SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Alexion Pharmaceuticals, Inc
-------------------------
(Name of Issuer)
COMMON STOCK
--------------------------------
(Title of Class of Securities)
015351109
----------------
(CUSIP Number)
August 5th, 2003
---------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check appropriate box to designate the rule pursuant to which this
Schedule is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
- -------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
PICTET FUNDS - BIOTECH
- -------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |_|
(b) |X|
- -------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- -------------------------------------------------------------------------
5 SOLE VOTING POWER
990'028
---------------------------------------------------------
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY
OWNED BY ---------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON
WITH ---------------------------------------------------------
8 SHARED DISPOSITIVE POWER
- -------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
990'028
- -------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|_|
- -------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.44%
- -------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
INVESTMENT FUND
- -------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
Item 1.
(a) Name of Issuer: Alexion Pharmaceuuticals, Inc
(b) Address of Issuer's Principal Executive Offices:
352 Knotter Drive
Cheshire, Connecticut 06410
United States
Item 2.
(a) Name of Person Filing:
PICTET FUNDS - BIOTECH
(b) Address of Principal Business Office or, if none, Residence:
Luxembourg
(c) Citizenship: Luxembourg
(d) Title of Class Securities: Common Stock
(e) CUSIP Number: 015351109
Item 3.
Not applicable.
Item 4. Ownership
(a) Amount Beneficially Owned:
990'028
(b) Percent of Class: 5.44%.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
(ii) shared power to vote or to direct the vote:
(iii) sole power to dispose or to direct the disposition of:
(iv) shared power to dispose or to direct the disposition of:
Item 5. Ownership of Five Percent or Less of a Class
Not applicable.
Item 6.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not applicable.
Item 9. Notice of Dissolution of the Group
Not applicable.
Item 10. Certification
By signing below I certify that, to the best if my knowledge and belief,
the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose
or effect.
SIGNATURE
After reasonable inquire and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: August 5th, 2003
Patrick SCHOTT Tom OLINGER
-------------- --------------
-------------- -------------